2023-04-24-港交所-康诺亚－Ｂ_2022年度报告_177页_3mb

Keymed Biosciences Inc. 2022 Annual Report Summary

Executive Summary
Keymed Biosciences, a biotechnology company focused on developing innovative therapies for autoimmune and oncology treatments, reported significant progress in its pipeline products despite a revenue decline. The company's revenue for 2022 was 100.063 million RMB, a 9% decrease from 2021. Key developments include advancing CM310 (IL-4Rα antibody) into Phase 3 trials, securing a licensing agreement with AstraZeneca for CMG901 (antibody-drug conjugate), and expanding production capacity. However, the net loss widened to 303.6 million RMB, primarily due to increased R&D expenses (42% year-over-year).

Business Highlights

• Pipeline Progress: CM310, the core product, entered Phase 3 trials for atopic dermatitis. CMG901, in partnership with AstraZeneca, showed promising results in early trials. Three new product collaborations were established, and the company secured global partnerships for key oncology candidates.
• Sales Expansion: The company signed a major licensing deal with Sinopharm to co-develop IL-4Rα inhibitors in respiratory diseases, contributing to nearly all revenue in 2022.
• Financial Position: Gross profit margins improved slightly to 9.4%, but R&D intensity increased, reflecting the company's commitment to clinical advancements. The cash balance decreased by 10% year-over-year due to operational expenditures.

Management Discussion and Analysis

• R&D Focus: R&D expenses rose by 42% to 507.374 million RMB, driven by Phase 3 trial expansions for CM310 and other key candidates. The company emphasized its integrated drug development platform and collaborations to accelerate commercialization.
• Regulatory Milestones: The U.S. FDA granted breakthrough therapy designations for multiple candidates, while the China NMPA expedited submissions.
• Financial Challenges: Net loss widened to 303.597 million RMB, impacted by R&D investments and foreign exchange losses. The company maintained a capital-light strategy, raising funds through equity issuance.

Corporate Governance
The board comprises experienced executives and independent directors, with robust committees for audit, remuneration, and nomination. Compliance with Hong Kong Exchange Listing Rules was upheld, ensuring transparency and strong governance practices.

Risk Management
Key risks include drug development failures, regulatory delays, competition, and reliance on partnerships. The company mitigated risks through diversified financing and strategic alliances.

Auditor's Report
The audit report issued an unqualified opinion, reaffirming compliance with International Financial Reporting Standards (IFRS). No material discrepancies were found in the financial statements.

Financial Review

• Assets and Liabilities: Current assets totaled 2,415.28 billion RMB, with significant cash and deposits. Liabilities decreased slightly, reflecting prudent financial management.
• Cash Flow: Operating activities consumed cash, while investing activities focused on expanding manufacturing capacity. The company maintained sufficient liquidity to fund future growth.

Conclusion
Keymed Biosciences demonstrated strong R&D momentum in 2022, advancing its clinical pipeline and securing partnerships. While financial challenges persist, the company's strategic focus on innovation and collaboration positions it for future growth in the biopharma sector.